News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Hapoalim Securities Expects Eli Lilly and Company To Acquire Amylin Pharmaceuticals, Inc. Post Approval Of AMLN’s Bydureon
June 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Benzinga.com -- Analyst Jon LeCroy of Hapoalim Securities reiterates his "buy" rating on Amylin Pharmaceuticals (NASDAQ: AMLN). The target price for AMLN is set to $22.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Eli Lilly and Company
MORE ON THIS TOPIC
Mergers & acquisitions
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
January 26, 2026
·
1 min read
·
Tristan Manalac
Cancer
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments
January 22, 2026
·
2 min read
·
Tristan Manalac
Insights
From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
January 22, 2026
·
1 min read
·
Jennifer Smith-Parker
Cell therapy
After Cell Therapy Retreat, Novo Offloads Technologies in Deepened Aspect Pact
January 21, 2026
·
2 min read
·
Tristan Manalac
